Patrick Rivers

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 787 citations · Full text

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway et al. · New England Journal of Medicine · 2021 · 519 citations · Full text

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, July 2021–February 2022

Ashley Fowlkes, Sarang K. Yoon, Karen Lutrick et al. · MMWR Morbidity and Mortality Weekly Report · 2022 · 182 citations · Full text

Prevention and Attenuation of COVID-19 by BNT162b2 and mRNA-1273 Vaccines

Mark G. Thompson, Jefferey L. Burgess, Allison L. Naleway et al. · 2021 · 56 citations · Full text

Local Virus Circulation, Immunodeficiencies, Immunology +17

Interim Estimate of Vaccine Effectiveness of BNT162b2 (Pfizer-BioNTech) Vaccine in Preventing SARS-CoV-2 Infection Among Adolescents Aged 12–17 Years — Arizona, July–December 2021

Karen Lutrick, Patrick Rivers, Young M. Yoo et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 46 citations · Full text

Immunodeficiencies, Covid-19 Epidemiology, Vaccine Hesitancy +23